Answers are grounded in this paper and cite their sources.
TDF for highly viraemic mothers was well tolerated and reduced vertical transmission of HBV in a real-world setting. There were no safety concerns during the postpartum 28-week follow-up. Registry number: Chinese Clinical Trial Registration No. ChiCTR-OIC-17010869.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: